Abstract:HIV-1 envelope (Env) gp120 is an important target for neutralizing antibody (Ab) responses against the virus; however, developing gp120 vaccines that elicit potent and broad neutralizing Abs has proven to be a formidable challenge. Previously, removal of an N-linked glycan at residue 448 by an N to Q mutation (N448Q) has been found to enhance the in vitro antigenicity of neutralizing epitopes in the V3 loop. In this study the mutated gp120 was first compared with wild type gp120 for immunogenicity in mice using a DNA prime and protein boost immunization regimen. The N448Q mutant did not elicit higher titers of anti-gp120 serum Abs and failed to generate anti-V3 Abs. The sera also had no virus-neutralizing activity, even though the mutant induced higher levels of lymphoproliferation and cytokine production. Subsequently, the N448Q mutant was used to construct an immune complex vaccine with the anti-CD4 binding site monoclonal antibody (mAb) 654. The N448Q/654 complex stimulated comparably high levels of serum Abs to gp120 and V3 as the wild type complex. However, Abs against the C1 and C2 regions in the gp120 core were more elevated. Importantly, the mutant complex also elicited higher titers of neutralizing Abs activity than the wild type counterpart. Similar results were achieved with a complex made with gp120 bearing an N448E mutation, confirming the importance of the N448-linked glycan in modulating gp120 immunogenicity. Neutralizing activity was directed to V3 and other undefined neutralizing epitopes. Improved immunogenicity of the immune complexes correlated with alterations in exposure of V3 and other Ab epitopes and their stability against proteases. These data demonstrate the advantage of combining site-specific N-glycan removal and immune complex formation as a novel vaccine strategy to improve immunogenicity of targeted Ab epitopes on critical regions of HIV-1 gp120.

Comparison of Antibody Immune responses to different HIV-1 Envelope Glycoprotein Mutants.

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Immunogenicity Analysis of HIV-1 06044 Gp140 Trimer Envelope

Immunogenicity Comparison Between Codon Optimized HIV-1 CRF BC_07 Gp140 and Gp145 Vaccines.

Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140

Deglycosylation of Hiv-1 Ae Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous Hiv-1 Clade

Expression and Identification of Immunological Activities of the HIV‐gp120N‐Human Interferon Gamma Fusion Protein

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

Levels of N-linked Glycosylation on the V1 Loop of HIV-1 Env Proteins and Their Relationship to the Antigenicity of Env from Primary Viral Isolates.

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

HIV-1 Env DNA Prime Plus Gp120 and Gp70-V1v2 Boosts Induce High Level of V1V2-specific IgG and ADCC Responses and Low Level of Env-specific IgA Response: Implication for Improving RV144 Vaccine Regimen

Construction and Immunogenicity Analysis of a Vaccine Against HIV-1 AE Recombinant

Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B｀/C and A/E recombinant HIV-1 strains

Enhancement of Gag-Specific but Reduction of Env- and Pol-Specific Cd8(+) T Cell Responses by Simian Immunodeficiency Virus Nonstructural Proteins in Mice

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques (P4503)

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice